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Abstract
We examined the promoter hypermethylation of tumor-
suppressor genes RASSF1A and TSLC1, quantitated
EBV DNA load in nasopharyngeal carcinoma (NPC) tis-
sues (T tissues), and matched tumor-adjacent tissues
outside 0.5 cm (P tissues) and outside 1.0 cm (Z tis-
sues) to evaluate the role of promoter hypermethyla-
tion of RASSF1A and TSLC1 as well as viral load in
the pathogenesis of NPC. Methylation-specific poly-
merase chain reaction (PCR) for RASSF1A and TSLC1
and quantitative real-time PCR analysis of EBV DNA
were performed on matched T, P, and Z tissues (n = 28)
as well as chronic nasopharyngitis tissues (n = 8).
Hypermethylated RASSF1A was frequently detected
in the T (82%) and P tissues (75%), but less frequently
in Z tissues (46%). The average quantities of EBV DNA
(copies/Mg DNA) in matched T, P, and Z tissues were
673,000, 90,000, and 7000. The differences of promoter
hypermethylation of RASSF1A and EBV viral load
among T, P, and Z tissues were statistically signifi-
cant, with more frequent methylation and higher viral
load detected when tissues examined were nearer
to the NPC tissues. Our results suggest that aberrant
hypermethylation of RASSF1A and high EBV load
might be important events in NPC pathogenesis, and
they may be useful molecular diagnostic markers for
this cancer.
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Introduction
Nasopharyngeal carcinoma (NPC) is a malignancy particu-
larly prevalent in Southern China and Southeast Asia.
Various studies indicate that the development of NPC is a
multistage process involving multiple factors. Genetic pre-
disposition and epigenetic alterations, Epstein-Barr virus
(EBV), and environmental factors including dietary habits
have been suggested to play roles in the development of
NPC [1,2].
3p21.3 is a chromosome region of particular significance
to NPC [3,4]. Loss of heterozygosity (LOH) and comparative
genomic hybridization (CGH) analyses indicate a high inci-
dence of allelic loss of 3p in NPC. Microsatellite marker dele-
tion and familial NPC pedigree analyses suggest that the
NPC-related locus is 3p21.3 [4–7]. Many tumor-suppressor
genes locate on the 3p21.3 region, including the NPC-related
tumor-suppressor gene RASSF1A [8,9]. Lost or altered
expression of this gene has been associated with the patho-
genesis of a variety of cancers. Aberrant promoter hyper-
methylation of RASSF1A occurs frequently in NPC [10–13].
Inactivation of RASSF1A was found to be related with the hy-
permethylation of CpG island in its promoter region. 11q22–23
is another important tumor-suppressive region in NPC, involv-
ing candidate tumor-suppressor gene TSLC1. Expression of
TSLC1 was downregulated by promoter hypermethylation in
NPC cell lines [14].
EBV, also referred to as the human herpesvirus-4 (HHV-4),
is a double-strand DNA gamma herpesvirus with a genome of
172 kb [15]. EBV is directly associated with human malignan-
cies. EBV infection occurs worldwide and most people become
infected during their lifetime. Infection with EBV usually occurs
at a very early age, particularly in developing countries, and
is closely associated with NPC and Burkitt’s lymphoma. In
contrast, in developed countries, most people are infected
during adolescence or young adulthood, associated with
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infectious mononucleosis (IM). Basically, there exist two
cell types susceptible to EBV infection: epithelial cells located
in human oropharynx/nasopharynx and B-lymphocytes. EBV
is strongly associated with NPC, an epithelial-derived cancer
[15]. Many evidences indicate that EBV may be one of the
most important factors involved in the tumorigenesis of
NPC, but the exact role of EBV in NPC pathogenesis is
not clear yet.
In this study, we detected the promoter hypermethylation
of RASSF1A and TSLC1 genes, quantitatively analyzed the
EBV DNA load in NPC tissues, and matched tumor-adjacent
tissues to evaluate the role of promoter hypermethylation of
RASSF1A and TSLC1 as well as EBV load in the develop-
ment of NPC.
Materials and Methods
Specimens
Twenty-eight matched tumor and tumor-adjacent tissues
as well as eight chronic nasopharyngitis tissues were ob-
tained from the Pathology Department of Xiangya Hospital
(Hunan, China), with the consent of patients according to
the regulation of university policy. Detailed information of
these patients was summarized in Tables 1 and 2. Speci-
mens were snap-frozen in liquid nitrogen and subsequently
stored at 80jC. Hematoxylin–eosin (HE)-stained sections
were examined for the presence or absence of tumor cells,
as well as tumor cell density. Only samples containing more
than 70% of tumor cells were selected for T tissues. P and
Z tissues were defined as tissues located 0.5 and 1.0 cm
outside of visible NPC lesions, respectively. Histopathologic
examination indicated that P tissues had mild, moderate,
to severe presence of atypical hyperplastic cells, and were
infiltrated by a number of lymphocytes. The Z tissues had
a mild presence of atypical hyperplastic cells and were
also infiltrated by inflammatory cells [16].
Table 1. Clinical Information of Patients with Chronic Nasopharyngitis;
Summary of MSP Results of RASSF1A and TSLC1, and EBV DNA Quan-
tities in Chronic Nasopharyngitis Tissues.
Patient
Number
Sex Age
(years)
Methylation
Status at
RASSF1A
Methylation
Status at
TSLC1
EBV
(copies/mg
DNA)
CN1 F 62   5.040  102
CN2 M 38   6.493  102
CN5 M 19   10.95  102
CN10 F 13   0
CN20 F 52   20.86  102
CN2a F 51   0.089  102
CN21 F 60   0
CN50 M 50   2.564  102
CN: patients with chronic nasopharyngitis; () no hypermethylation detected.
Table 2. Clinical Information of Patients with NPC; Summary of MSP Results of RASSF1A and TSLC1, and EBV DNA Quantities in Matched T, P, and Z Tissues.
Patient Number Sex Age (years) TNM Methylation Status at RASSF1A Methylation Status at TSLC1 EBV (copies/mg DNA)
T P Z T P Z T P Z
29 M 64 IVa    +   3.110  102 4.211  102 19.63  102
30 M 42 IIb + + + + + + 395.2  102 93.80  102 0
31 F 31 IIb + + +    9307  102 4634  102 210.8  102
32 M 45 IIb + + + + +  868.0  102 917.0  102 353.8  102
36 M 68 IVa + + + + +  665.0  102 483.8  102 30.78  102
40 M 40 IIb + +  + +  8480  102 2188  102 19.27  102
44 F 50 IVb +   + + + 2149  102 4.350  102 0
46 M 30 I + + + + + + 29190  102 3.247  102 0.816  102
48 M 37 III + +     37580  102 331.4  102 0
49 M 28 III + +     4650  102 105.4  102 17.22  102
50 M 26 IIb       9580  102 22.23  102 3.723  102
51 M 32 IIb +   + + + 6880  102 10.62  102 8.970  102
54 M 54 IIa    + + + 17.92  102 2.615  102 0
56 M 37 IIb + + + + + + 21720  102 889.0  102 192.8  102
58 F 42 IIb    +   430.5  102 37.59  102 3.738  102
59 F 35 IIb    + + + 434.0  102 10.38  102 3.620  102
60 M 41 IIb + +  + + + 153.3  102 29.31  102 7.110  102
62 M 52 IIa + + +    5620  102 373.0  102 2.201  102
64 M 55 IIa + +  + + + 1142  102 878.0  102 0.256  102
61 F 62 IVb + + +    6.960  102 3.982  102 0
66 M 60 IIa + +  + + + 10190  102 0 0
70 M 55 III + + + + + + 98.00  102 29.41  102 0.107  102
71 F 45 III + +  + + + 2851  102 2283  102 23.97  102
72 F 38 IIb + + +    10510  102 712.0  102 3.460  102
73 F 48 I + + + + + + 12330  102 1310  102 920.0  102
76 M 45 III + + +    421.0  102 0.268  102 0
77 M 55 IVb + + + + + + 1807  102 1031  102 210.8  102
79 F 55 IVa + +     11040  102 760.0  102 40.30  102
TMN: tumor–node–metastasis stage; (+) hypermethylation; () no hypermethylation detected.
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EBER-ISH (EBV-Encoded Small RNA–In Situ
Hybridization)
Five cases of matched T, P, and Z tissues were ran-
domly selected. ISH was performed using the EBER-ISH kit
(PanPath Co., Amsterdam, The Netherlands) according to the
manufacturer’s instruction. Briefly, after the sections were
dewaxed with dimethyl benzene, dehydrated with alcohol,
and predigested with pepsin, hybridization solution contain-
ing the fluorescein-conjugated EBV nucleic acid probe was
applied. After application of alkaline phosphatase–conjugated
antibody against fluorescein isothiocyanate, nitroblue tetra-
zolium chloride/bromochloroindolylphosphate (NBT/BCIP)
was applied as the chromogen. Dark brown nuclear staining
was interpreted as a positive hybridization signal.
Cell Lines and Culture Conditions
The NPC cell lines were cultured in RPMI 1640 supple-
mented with 10% FCS (Invitrogen, Carlsbad, CA).
DNA Preparation
Genomic DNA from matched T, P, and Z tissues as well
as chronic nasopharyngitis tissues were prepared using
an improved method of extracting high-molecular-weight
DNA with phenol/chloroform as described inMolecular Clon-
ing [17]. Briefly, tissues were ground in liquid nitrogen, dis-
solved in 500 ml of Tris/NaCl/EDTA/SDS with proteinase K
(100 mg/ml), incubated at 55jC for 2 hours, heated at 65jC
for 15 minutes to inactivate the enzyme, and then extracted
by phenol/chloroform followed by precipitation with 70% of
ethanol. Finally, pellets of DNA were dissolved in DNase-
free water and the concentrations were determined before
being stored at 80jC.
Bisulfite Treatment
DNA was subjected to bisulfite treatment [18] according
to the protocol of Tao et al. [19], with a little modification.
Briefly, 2 mg of genomic DNA was denatured in 0.3 M NaOH
for 10 minutes at 37jC. The denatured DNA were diluted in
300 ml of freshly prepared solution of 10 mM hydroquinone
and 4.8 M sodium bisulfite, and incubated for 4 hours at
55jC in darkness. After the incubation, the DNA samples
were desalted through a column provided by genome DNA
clean-up system (TaKaRa Bio Inc., Shiga, Japan). The
eluted DNA was treated with 0.3 M NaOH for 8 minutes at
room temperature, and precipitated with acetate ammonia
and ethanol. The bisulfite-modified genomic DNA was re-
suspended in 20 ml of TE buffer and stored at 20jC.
Methylation Analysis
Methylation-specific polymerase chain reaction (MSP)
was performed according to the TaKaRa HS Taq kit pro-
tocol. Primers for MSP were described by Qiu et al. [11]
for RASSF1A, and redesigned for TSLC1 according to the
reports by Kuramochi et al. [20], Fukuhara et al. [21], and
Lung et al. [14]. For each reaction, 1 ml of sodium bisulfite–
treated DNA was added to 24 ml of reaction buffer (1.25 mM
dNTPs, 16.6 mM (NH4)2SO4, 6.7 mM MgCl2, and 1.5 U of
HS Taq polymerase; TaKaRa Bio Inc.) containing 100 ng of
forward and reverse primers specific to the methylated or
unmethylated DNA sequences. Conditions for amplification
of DNA were 94jC for 4 minutes, followed by 35 cycles
of 94jC for 30 seconds, 55jC for 30 seconds (53jC for
TSLC1), and 72jC for 30 seconds, with a final extension of
72jC for 5 minutes.
Sequencing of MSP Products of RASSF1A and TSLC1
Both U (reactions using primers specific for unmethyl-
ated CpG sites) and M (reactions using primers specific
for methylated CpG sites) products of the RASSF1A and
TSLC1 MSP from one T tissue were excised from agarose
gels and purified by the PCR product purification system
(TaKaRa). Subsequently, sequencing reactions were per-
formed separately on the purified U and M products by 377
ABI PRISM DNA sequencer (Shanghai BoYa Company,
Shanghai, China).
RT-PCR
The expression of RASSF1A and TSLC1 in NPC tis-
sues and NPC cell lines as well as chronic nasopha-
ryngitis tissues was examined by RT-PCR analysis. Total
RNA was isolated by TRIZOL reagent. Two micrograms of
total RNA was subjected to cDNA synthesis using a Re-
verse Transcription System according to the manufac-
turer’s protocol (Promega, Madison, WI). PCR analysis of
RASSF1A expression was carried out with primers ac-
cording to Qiu at al. [11], and primer sequences of TSLC1
are 5V-ATGAAATGCCTCAACACGCCGTAC-3V and 5V-
TCTGCTGCGTCATCGGCTC CT-3V.
Real-Time PCR
EBV DNA copies in matched T, P, and Z tissues as well
as chronic nasopharyngitis tissues were measured by real-
time quantitative PCR analysis. The PCR primers and DNA
probe with fluorescent dye (FAM) and TAMRA were de-
signed according to Lo et al. [22] and synthesized by Dalian
Baosheng Life Technologies, Inc. (Dalian, China), and used
according to the manufacturer’s protocol. In brief, PCR was
set up in a total volume of 25 ml, including 2.5 ml of 10 buffer,
300 nM of each of the primers, 25 nM of the fluorescent
probe, 200 nM dNTPs, 3 mM MgCl2, 2.5 ml of DNA template,
and 1 U of Taq DNA polymerase (Promega). The reactions
were performed and analyzed using the Double Fluorescent
Quantitative PCR System (Light Cycler; Roche, Morristown,
NJ). Parameters for PCR were as follows: 95jC for
5 minutes, followed by 40 cycles of 94jC for 15 seconds
and 56jC for 1 minute.
Statistical Analysis
For comparison of hypermethylation level and EBV quan-
tities in matched samples of T, P, and Z tissues, odds ratios
were calculated and evaluated using chi-square analysis
for hypermethylation data and analysis of variance (ANOVA)
for EBV data. We used the logarithm of EBV data for sta-
tistical analysis in this study. P < .05 was considered as
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statistically significant. The statistical analyses were per-
formed using the Excel software (Microsoft Corp., Redmond,
WA) and statistical software SPSS Version 11.0 (SPSS Inc.,
Chicago, IL).
Results
Detection of EBV Infection in NPC and Matched
Adjacent Tissues
EBER-ISH detected many EBV+ tumor cells in all five
cases of T tissues with strong positive signals, but only
scattered EBV+ cells in all five cases of P tissues. However,
all five cases of Z tissues were EBER (Figure 1).
Methylation Status and Expression of RASSF1A and TSLC1
in NPC Cell Lines
The methylation status of RASSF1A and TSLC1 in
all currently available NPC cell lines (n = 11) was examined
by MSP. Promoter hypermethylation of RASSF1A and
TSLC1 was detected in the majority of cell lines. RT-PCR
results showed that the expression levels of both genes
were inversely correlated with their promoter methylation
status (Figure 2).
Hypermethylation of RASSF1A in Matched T, P,
and Z Tissues
Because the aberrant methylation of RASSF1A and
TSLC1 was frequently detected in NPC cell lines, we further
investigated the methylation of these two tumor-suppressor
genes in NPC tumors and the tumor-adjacent tissues. By
MSP, the frequencies of promoter hypermethylation of RA
SSF1A in matched T, P, and Z tissues were 82% (23 of
28), 75% (21 of 28), and 46% (13 of 28), respectively. No
promoter hypermethylation of RASSF1A was detected in
chronic nasopharyngitis tissues (zero of eight). All P tissues
with hypermethylation of RASSF1A also had methylation in
their matched T tissues. All Z tissues with hypermethylated
RASSF1A also had methylation in matched Tand P tissues.
The results are summarized in Tables 1 and 2, and the rep-
resentative MSP results are shown in Figure 3.
A statistically significant difference in hypermethylation
levels among matched T, P, and Z tissues was found, and
there were a significant difference between P and Z tissues,
Figure 1. Nuclear staining for EBER by ISH in NPC and matched tumor-adjacent tissues (original magnification, 400). (A) Strong positive signals were detected
in many carcinoma nuclei of T tissues. (B) Weak to strong positive signals were detected in the nuclei of some atypical hyperplasic cells of P tissues. (C) No positive
signal was detected in any cell of Z tissues.
Figure 2.Methylation status and expression of RASSF1A and TSLC1 in NPC
cell lines. Promoter hypermethylation of RASSF1A and TSLC1 was detected
in the majority of cell lines with expression downregulated or silenced.
Figure 3. Detection of hypermethylation of RASSF1A and TSLC1 in matched
T, P, and Z tissues as well as chronic nasopharyngitis tissues. MSP analysis
was performed using primers specific for both promoters. PCR products were
visualized after electrophoresis on a 2% agarose gel (T: NPC tissues; P:
tumor-adjacent tissues outside 0.5 cm; Z: tumor-adjacent tissues outside
1.0 cm; CN: chronic nasopharyngitis tissues).
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but no significant difference between T and P tissues (Fig-
ure 4A). Hypermethylation levels in T and P tissues were
significantly higher than that in matched Z tissues (P = .002
and .029, respectively), and the hypermethylation level in
Z tissues was significantly higher than that in chronic naso-
pharyngitis tissues (P = .016).
Hypermethylation of TSLC1 in Matched T, P, and Z Tissues
The frequencies of TSLC1 promoter hypermethylation
in matched T, P, and Z tissues were 68% (19 of 28), 61%
(17 of 28), and 50% (14 of 28), respectively. No promoter
hypermethylation of TSLC1 was detected in chronic naso-
pharyngitis tissues (zero of eight). All P tissues with hyper-
methylation of TSLC1 also had methylation in their matched
T tissues. All Z tissues with hypermethylation TSLC1 also
had methylation in the matched Tand P tissues. Three cases
exhibited aberrant promoter hypermethylation in T tissues
and matched P tissues, but not in Z tissues. Two cases
exhibited aberrant promoter hypermethylation in T tissues,
but not in matched P and Z tissues. Fourteen cases exhibited
Figure 4. Histogram of frequencies of aberrant promoter hypermethylation of RASSF1A (A) and geometric mean of EBV quantities (B) in T, P, and Z tissues of
NPC patients. They followed a similar trend from high to low in these samples.
Figure 5. Sequencing analysis of M-MSP and U-MSP products for RASSF1A from NPC tissues (patient 71). For M-products, all cytosines were changed to
thymines, except cytosines in CpG dinucleotide. The changes are underlined and M- and U-primers of MSP are double-underlined.
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aberrant promoter hypermethylation in T, P, and Z tissues.
The results were listed in Tables 1 and 2, and representative
MSP results are shown in Figure 3.
No statistically significant difference in TSLC1 hyper-
methylation among matched T, P, and Z tissues was found.
Sequencing Confirmation of Methylated and Unmethylated
PCR Products
The M-MSP and U-MSP products amplified from one
T tissue (patient 71) for either M or U primers of RASSF1A
and TSLC1 were sequenced. The sequencing result showed
that all cytosine residues in the sequence were converted
to thymines, except for cytosine residues in CpG dinucleo-
tides, indicating the presence of methylated cytosines in
these CpG dinucleotides; the sequencing result of U-PCR
product showed that all cytosine nucleotides, including those
within CpG dinucleotides, were converted to thymines, indi-
cating complete conversion of all cytosines to uracils by
sodium bisulfite and the presence of unmethylated CpG
sites. The representative sequencing results of M- and U-
sequences of RASSF1A were shown in Figure 5.
EBV DNA Quantities in Matched T, P, and Z Tissues
as Well as Chronic Nasopharyngitis Tissues
Quantitative analysis of EBV DNA was performed on all
matched T, P, and Z tissues. EBV DNA was detectable in 28
(100%) T tissues, and the average EBV DNA quantity was
6730  102 copies/mg DNA. EBV DNA was detectable in 27
(96%) matched P tissue samples of NPC patients, and
the average EBV DNA quantity was 900  102 copies/mg
DNA. EBV DNA was detectable in 21 (75%) matched Z tis-
sues, and the average EBV DNA quantity was 70  102
copies/mg DNA. EBV DNA was also detectable in six (75%)
chronic nasopharyngitis tissues, but the average EBV DNA
quantity was only 6  102 copies/mg DNA (Tables 1 and 2).
A statistically significant difference of EBV DNA quantities
among T, P, and Z tissues and chronic nasopharyngitis
tissues was discovered (Figure 4B). The EBV DNA quan-
tities in P tissues were significantly lower than those in
matched T tissues (P = .027), whereas the EBV DNA
quantities in Z tissues were significantly lower than those
in matched P tissues (P < .01). The EBV DNA quantities
in chronic nasopharyngitis tissues were lower than those
matched tissues in NPC patients (P < .01).
Expression of RASSF1A and TSLC1 in T Tissues
and Chronic Nasopharyngitis Tissues
Expression of RASSF1A and TSLC1 in T tissues and
chronic nasopharyngitis tissues was examined by RT-PCR.
Figure 6 shows that chronic nasopharyngitis tissues ex-
pressed a relatively higher level of both RASSF1A and
TSLC1 mRNA when compared with T tissues.
Discussion
NPC is an endemic cancer with high incidence in Southeast
Asia and Southern China. Both physical mapping and func-
tional studies have assigned NPC-related tumor-suppressor
gene(s) to 3p21.3. RASSF1A is a critical tumor-suppressor
gene located at this locus, which has been shown to be
frequently inactivated by promoter hypermethylation in
Hong Kong and Singaporean NPC, both in NPC cell lines
and primary tumors [9–11]. Although these studies demon-
strated that promoter hypermethylation inactivated RASSF1A
expression in NPC tissues and cell lines, they could not
elucidate whether promoter hypermethylation is indeed in-
volved in NPC tumorigenesis, or just a passenger phenome-
non after the development of NPC.
Although our locality (Hunan Province, China) is not
located in the highly prevalent area of NPC like Hong Kong,
we still detected aberrant promoter methylation of RASSF1A
in 82% of NPC tissues, similar to the previous reports of
NPC tumors from Hong Kong and Singapore. We also de-
tected aberrant methylation in 75% of P tissues and 46% of
Z tissues of NPC patients. These results demonstrated the
lowest level of RASSF1A methylation in Z tissues, a mod-
erate level of methylation in P tissues, the highest methyla-
tion level in T tissues, and no aberrant methylation in chronic
nasopharyngitis tissues. There are statistically significant
differences in hypermethylation levels among T, P, and Z
tissues. Our results suggest that: 1) aberrant promoter
methylation of RASSF1A is a critical event in the develop-
ment of NPC because no aberrant methylation was detected
in chronic nasopharyngitis tissues; and 2) aberrant promoter
methylation of RASSF1A is an early event during the patho-
genesis of NPC because aberrant methylation of RASSF1A
exists in both Z and P tissues.
In our studies, RASSF1A and TSLC1 genes were both
frequently inactivated by promoter hypermethylation in NPC
tissues and NPC cell lines. The results confirmed that pro-
moter methylation plays a direct role in silencing both genes
in NPC and contributes to NPC pathogenesis.
EBV is a member of the herpesvirus family, widely asso-
ciated with human tumors. Although the association of EBV
with the development of NPC is well-established, the precise
role of EBV in the carcinogenic process remains unknown.
Humans appear to be the only reservoir for EBV. Infection
with the virus can lead to three different outcomes: 1) repli-
cation of the virus in epithelial cells permissive for EBV
proliferation; 2) latent infection of B-lymphocytes in the
presence of competent T-lymphocytes; and 3) stimulation
and immortalization of B-cells [15]. Previous studies have
demonstrated that EBV appears in many healthy subjects
Figure 6. Expression of RASSF1A and TSLC1 in chronic nasopharyngitis
tissues and T tissues. Chronic nasopharyngitis tissues expressed a relatively
higher level of both genes compared with T tissues (CN: chronic naso-
pharyngitis tissues; T: NPC tissues).
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as well as patients with other cancers [23–25]. In our
studies, the difference of EBV DNA levels among T, P, and
Z tissues and chronic nasopharyngitis tissues was statisti-
cally significant. Further analyses showed that there were
significant differences in EBV levels between either of the
two abovementioned tissues. The EBER-ISH results also
showed the different numbers of latent EBV-infected cell
among T, P, and Z tissues. The results indicated that EBV
copies were more abundant in regions nearer to the NPC
tissues, suggesting either an infiltration of EBV tumor cells
to adjacent area or a continuous malignant transformation
of nearby epithelial cells. Our study also demonstrated that
EBV is present in both NPC and healthy nasopharyngeal
tissues, but the EBV load in healthy subjects was far less
than that in NPC patients.
Aberrant promoter hypermethylation of RASSF1A and
EBV quantities in T, P, and Z tissues followed a similar trend
from high to low, suggesting a possible correlation between
them. The promoter hypermethylation levels of TSLC1 in
matched T, P, and Z tissues are not statistically significant,
although a larger-scale study is needed to confirm this ob-
servation. There was no evidence for possible correlation
between RASSF1A and TSLC1 methylation in this study.
In summary, our results indicate that promoter hyper-
methylation of both RASSF1A and TSLC1, and high EBV
DNA load were commonly found in NPC tissues. The differ-
ences of aberrant promoter hypermethylation of RASSF1A
and EBV levels between matched T, P, and Z tissues of NPC
patients were statistically significant, with both levels being
higher in tissues nearer to the NPC tissues. The results
suggest that both promoter hypermethylation of RASSF1A
and EBV infection might have occurred in the early phase of
the development of NPC, and there may be a direct corre-
lation between these two events.
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